A recent study from Washington University in St. Louis indicates a potential link between sleep and Alzheimer's disease. Researchers discovered that suvorexant, a commonly prescribed medication for insomnia, may reduce molecular markers related to Alzheimer's, specifically beta-amyloid and tau proteins, after just two nights of treatment.
Read More
Sleep is recognized as crucial for maintaining brain health, with past studies highlighting strong associations between sleep disorders and the onset of Alzheimer's. Disturbances in sleep may present as early indicators of cognitive decline before classic symptoms like memory loss manifest.
This research, spearheaded by Dr. Brendan Lucey, shows a slight decrease in toxic proteins in the cerebrospinal fluid of participants using suvorexant. However, Dr. Lucey cautions against viewing suvorexant as a preventive treatment at this point. The short duration and limited participant number mean further investigation is essential to confirm these findings over the long term.
Exploring the strategy of improving sleep to mitigate Alzheimer's risk represents a shift in treatment perspectives. Current therapies aimed at reducing harmful protein buildup have not been as effective as hoped. Research has indicated that quality sleep may significantly reduce the risk of cognitive decline, particularly in individuals over 60, where a decline in deep sleep can increase dementia risk by 27% annually.
Dr. Lucey advocates for better sleep hygiene and the treatment of sleep disorders, such as sleep apnea, as integral to preserving cognitive health. While this study, published in the Annals of Neurology, represents progress in understanding Alzheimer's, the quest for definitive treatments continues.